112 results about "Serum mirna" patented technology

The invention discloses miRNA (microribonucleic acid) biomarkers and a detection kit for ovarian cancer diagnosis. The microRNA biomarkers are composed of the following microRNAs: has-miR-193b-3p, has-miR-155-5p, has-miR-145-5p, has-miR-132-3p and has-miR-143-3p. The serological expression analysis on the five miRNAs has-miR-193b-3p, has-miR-155-5p, has-miR-145-5p, has-miR-132-3p and has-miR-143-3p of ovarian cancer with obvious para-carcinoma tissue expression differences (the differential expression level is greater than 2 folds, and the CT value in RT-PCR (reverse transcription-polymerase chain reaction) is less than 30) indicates that the five miRNAs have stable expression in serum, the serum miRNA expression has favorable consistency with the tissue, the expressions of the has-miR-193b-3p, has-miR-155-5p and has-miR-145-5p are enhanced, and the expressions of the has-miR-132-3p and has-miR-143-3p are lowered. The five miRNAs can be used as biomarkers for ovarian cancer diagnosis, and the sensitivity and specificity of combined diagnosis are obviously higher than the sensitivity and specificity of single-miRNA diagnosis.

The invention provides serum miRNA relevant to a chronic heart failure and application of the serum miRNA. The invention provides application of peripheral blood miRNAs to the chronic heart failure as biomarker risk assessment / diagnosis and prognosis. Hsa-miR-4491, hsa-miR-1285-3p, hsa-miR-665, hsa-miR-660-3p, hsa-miR-206, hsa-miR-1268b, hsa-miR-130a-3p and hsa-miR-330-3p have differential expressions in peripheral blood of heart failure patients. It is proved that the peripheral blood hsa-miR-665 and the like can perform specific diagnosis on the chronic heart failure, the expression level of the hsa-miR-665 and the like is relevant to ejection fraction, and the hsa-miR-665 has an assessment and prognosis effect. Thus, by detecting the expression level of the miRNAs, the existing chronic heart failure can be predicted and coordinately diagnosed, or prognosis of the chronic heart failure can be estimated.

The invention discloses a serum miRNA composition, which is at least one of the following serum miRNAs: hsa-miR-23a, hsa-let-7i, and hsa-miR-486. The invention also simultaneously provides a fluorescent quantitative detection primer composition for detection of type 2 diabetes mellitus. The composition comprises an RT primer, an FW primer and an RV primer of each miRNA in hsa-miR-23a, hsa-let-7i, and hsa-miR-486. By adopting the serum miRNA marker for early diagnosis of type 2 diabetes mellitus and cancer risk evaluation provided by the invention, a serum miRNA biomarker can be used for diagnosing whether a subject has the type 2 diabetes mellitus or early diagnosis of the type 2 diabetes mellitus and cancer risk evaluation.

The invention belongs to the fields of biotechnology and medicine, and relates to gout serum miRNAs biomarkers and a method for detecting the expression quantity thereof. The gout serum miRNAs biomarkers comprise hsa-miR-3146, hsa-miR-4449, hsa-miR-4531, hsa-miR-451a, hsa-miR-223-3p, hsa-miR-589-5p and hsa-miR-885-5p. These markers serving as important biological detection indexes of serum can be used for preparing tools such as gout diagnosis reagents or bio-chips and the like, have important value in clinical early accurate diagnosis of gout, provide theoretical basis for molecular level diagnosis of gout and research of gout serum miRNAs later, and have important theoretical significance and potential practical value.

The invention provides application of a serum miRNA biomarker, and relates to biomarkers. The serum miRNA biomarker comprises at least one of miR-34c, miR-1275, miR-375, miR-410 and miR-758. The serum miRNA biomarker can be applied to preparation of a reagent for detecting oligospermia and azoospermia. A serum miRNA biomarker composition comprises at least one of the miRNA and sequences of reverse transcription primers, forward primers and reverse primers of each miRNA, and can be applied to preparation of a reagent for detecting oligospermia and azoospermia. The determined close correlation between the miRNA combination and indexes of oligospermia and azoospermia cases can be used as the biomarker to screen and diagnose patients with oligospermia and azoospermia, and an efficient basis is provided to clinical individual intervention treatment.

The invention discloses an miRNA biomarker and a detection kit for thyroid cancer diagnosis. The miRNA biomarker comprises microRNAs, namely hsa-miR-193b-3p, hsa-miR-384, hsa-miR-145-5p, hsa-miR-424-5p and hsa-miR-143-3p. The five miRNAs, namely the hsa-miR-193b-3p, the hsa-miR-384, the hsa-miR-424-5p, the hsa-miR-145-5p and the hsa-miR-143-3p, in which expression differences between the thyroid cancer and para-carcinoma tissues are obvious (difference expression amount is larger than 2 folds, and the CT value in RT-PCR is smaller than 30), are subjected to serologic expression analysis; results show that the five miRNAs are expressed stably in serum, expression and organization of serum miRNAs have high uniformity, expression of the hsa-miR-193b-3p, the hsa-miR-384 and the hsa-miR-145-5p is regulated down, and expression of the hsa-miR-424-5p and the hsa-miR-143-3p is regulated up. The five microRNAs can serve as the miRNA biomarker for thyroid cancer diagnosis, and sensitivity and specificity of combined diagnosis are higher than those of single miRNA diagnosis remarkably.

The invention discloses a serum marker miR-301a with the sequence of SEQ ID NO. 1 and application of a kit prepared by adopting the miR-301a marker as a molecular marker in early diagnosis for pancreatic cancer induced by pancreatitis and curative effect monitoring. The kit prepared by adopting the miR-301a marker can conveniently and quickly detect the expression level of miRNA, it is not necessary to customize special primer sequences additionally, and by detecting the blood plasma, pancreatic cancer tissue and expression level of the miR-301a in a pancreatic cancer cell line of a patient suffering from pancreatitis and pancreatic cancer, the Pearson correlation test is utilized for analyzing the relationship between the miR-301a and a known traditional marker of pancreatitis and comparing the miR-301a with the known traditional marker of pancreatitis; through a receiver operating characteristic curve (ROC), the identification capacity of the miR-301a and joint detection by the miR-301a and CA199 in pancreatic cancer diagnosis and pancreatic cancer staging is evaluated, and the potential value of the miR-301a marker of the blood plasma in early diagnosis for pancreatic cancer induced by pancreatitis is investigated to provide a new theory and a new test basis for early diagnosis and targeted therapy of pancreatic cancer from the miRNA level.

The invention discloses a serum miRNA marker related to auxiliary diagnosis for squamous lung cell carcinoma and an application thereof. The marker is one or more of miR-106a-5p, miR-20a-5p and miR-93-5p. As a novel biomarker, the serum miRNA has the characteristics of high stability, minimal invasion, easiness in acquiring, sensitivity and specificity. Such a molecular marker can be developed and utilized to supply a new direction for diagnosing and further treating various diseases including tumor. According to the research, the serum miRNA marker for squamous lung cell carcinoma with clinical diagnosis potential can be more specifically acquired. The research proves that the miRNA as a noninvasive marker for diagnosing the squamous lung cell carcinoma has reliability and repeatability.